The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of A Randomized Double–Blind, Placebo–Controlled Trial
Open accessAbstract
A randomized double–blind, placebo–controlled efficacy trial of hepatitis B immune globulin (HBIG) for prevention of the mother–to–infant transmitted HBsAg carrier state was conducted in Taiwan where the carrier rate in the general population is 15 to 20%. HBIG was given immediately after birth to infants of e antigen positive HBsAg carrier mothers, and all infants were followed for at least 15 months. Among 61 placebo recipients, the carrier rate was 92%; compared with 26% among 57 infants who received 0.5 ml HBIG at birth, 3 months, and 6 months, and 54% among 67 infants who received a single 1.0 ml dose of HBIG at birth only. Efficacy was 71 and 42%, respectively, for the two treatment schedules. The most common response of HBIG–treated infants was passive–active immunization which was 27% in the single–dose group and 61% in the three–dose group. Some of the infants who became carriers were probably infected as HBIG protection waned, and we expect that higher efficacy can be achieved by hepatitis B vaccine in conjunction with HBIG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
Self-citationVertical Transmission of Hepatitis B Antigen in Taiwan
Stevens, C. E., Beasley, R. P., Tsui, J., & Lee, W.-C. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504102921503 · Cited by 1,022
Self-citationOkada, K., Kamiyama, I., Inomata, M., Imai, M., Miyakawa, Y., & Mayumi, M. (1976) · New England Journal of Medicine · doi:10.1056/nejm197604012941402 · Cited by 728
THE e ANTIGEN AND VERTICAL TRANSMISSION OF HEPATITIS B SURFACE ANTIGEN
BEASLEY, R. P., TREPO, C., STEVENS, C. E., & SZMUNESS, W. (1977) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112370 · Cited by 611
Self-citationPostnatal Infectivity of Hepatitis B Surface Antigen-Carrier Mothers
Beasley, R. P., & Hwang, L.-Y. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.2.185 · Cited by 280
Self-citationPalmer Beasley, R., Lin, C.-C., Wang, K.-Y., Hsieh, F.-J., Hwang, L.-Y., Stevens, C., Sun, T.-S., & Szmuness, W. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90832-1 · Cited by 242
Self-citationSEVERELY DISTURBED ADOLESCENTS
(1970) · The Lancet · doi:10.1016/s0140-6736(70)90823-8 · Cited by 171
Cited by
Epidemiology of Hepatocellular Carcinoma
Bosch, F. X., Ribes, J., Cléries, R., & Díaz, M. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.12.009 · Cited by 1,131
Beasley, R. P., CHIN-YUN LEE, G., Roan, C.-H., Hwang, L.-Y., Lan, C.-C., Huang, F.-Y., & Chen, C.-L. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90624-4 · Cited by 813
Self-citationMascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4009-4018.1999 · Cited by 783
A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi206 · Cited by 743
Shibata, R., Igarashi, T., Haigwood, N., Buckler–White, A., Ogert, R., Ross, W., Willey, R., Cho, M. W., & Martin, M. A. (1999) · Nature Medicine · doi:10.1038/5568 · Cited by 539
Metadata
- Authors
- Beasley, P. R., Hwang, L.-Y., Stevens, C. E., Lin, C.-C., Hsieh, F.-J., Wang, K.-Y., Sun, T.-S., & Szmuness, W.
- Venue
- Hepatology
- Published
- 1983-03
- Volume
- 3
- Issue
- 2
- Pages
- 135-141
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2099659744
- Cited by
- 290
- References
- 7
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.